Skip to content
DataLookout
Menu

AMAZE 7NCT07668414

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Study sites: 43 to 45
    • Eligibility criteria expanded, about 5 words
  2. Minor Trial sites reduced: 46 → 43 locationsv2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Relative change in body weight
Timeframe: From week 0 to week 84

Secondary (1)

Change in waist circumference

Arms and interventions

ZenagamtideExperimental

Participants will receive Zenagamtide and placebo matched to semaglutide subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

Semaglutide dose 1Active comparator

Participants will receive semaglutide dose 1 and placebo matched to zenagamtide subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

Semaglutide dose 2Active comparator

Participants will receive semaglutide dose 2 and placebo matched to zenagamtide subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.

Drugs: Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)

Sites

45 sites in 1 country